ATOS — Atossa Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Atossa Therapeutics Issues Letter To Shareholders
Brief: Atossa Therapeutics Announces The Appointment Of Eric Van Zanten As Vice President, Investor And Public Relations
Brief: Atossa Therapeutics Reports Q3 Loss Per Share Of $0.06
Brief: Atossa Therapeutics Inc To Acquire Stake In Privately Held Dynamic Cell Therapies
Live Markets: UK retail: risks now more balanced
Live Markets: Surging wheat prices ramp up inflationary pressures
Live Markets: Screening for credit risk in Europe
U.S. STOCKS ON THE MOVE-Starbucks, Keycorp, Vaxcyte
Atossa rises as FDA lifts clinical hold on breast cancer study
Brief: Atossa Therapeutics Inc Receives Authorization From FDA
Brief: Atossa Therapeutics Says Received Non-Compliance Letter From Nasdaq
Advent to test choppy buyout market with sale of France's IDEMIA -sources
U.S. RESEARCH ROUNDUP- Analog Devices, Bath & Body Works, Synopsys
Atossa Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Atossa Therapeutics Announces Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: Atossa Therapeutics Plans To Complete Required Ongoing Studies And Submit Information Required By FDA By End Of Q3 2022
Atos CFO to exit; Nathalie Sénéchault to take over
Brief: Atossa Therapeutics Says On June 1, Submitted An Investigational New Drug To FDA For Atossa's Proprietary Oral (Z)-Endoxifen Capsules
Atossa Therapeutics Inc reports results for the quarter ended in March - Earnings Summary